tiprankstipranks
Trending News
More News >
XRF Scientific Limited (AU:XRF)
ASX:XRF
Australian Market

XRF Scientific Limited (XRF) AI Stock Analysis

Compare
25 Followers

Top Page

AU

XRF Scientific Limited

(Sydney:XRF)

Rating:70Outperform
Price Target:
AU$2.00
▲(28.21%Upside)
XRF Scientific Limited's overall stock score is bolstered by strong financial performance, characterized by robust profit margins and low leverage, which indicate a stable financial position. However, technical analysis shows mixed signals, and the high P/E ratio suggests the stock may be overvalued, which partially offsets the positive financial metrics.

XRF Scientific Limited (XRF) vs. iShares MSCI Australia ETF (EWA)

XRF Scientific Limited Business Overview & Revenue Model

Company DescriptionXRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries in Australia, Canada, and Europe. It operates through Capital Equipment, Precious Metals, and Consumables segments. The Capital Equipment segment designs, manufactures, and services automated fusion equipment, and high temperature test and production furnaces, as well as general laboratory equipment. The Precious Metals segment manufactures products for the laboratory and platinum alloy markets. The Consumables segment manufactures chemicals and other supplies for analytical laboratories. The company was founded in 1972 and is based in Osborne Park, Australia.
How the Company Makes MoneyXRF Scientific Limited generates revenue through the sale of its advanced equipment and consumables to laboratories and facilities involved in material analysis and testing. Key revenue streams include the sale of fusion equipment, which is used for preparing samples for X-ray fluorescence (XRF) and inductively coupled plasma (ICP) analysis, and the sale of associated consumables like fluxes and crucibles. The company also earns from providing technical support and maintenance services for its equipment. Significant partnerships with mining companies and research institutions contribute to a steady demand for its products, driving consistent revenue growth.

XRF Scientific Limited Financial Statement Overview

Summary
XRF Scientific Limited demonstrates strong financial performance with robust revenue growth, high profit margins, and low leverage. The company maintains financial stability and operational efficiency, though attention is needed on cash flow trends to ensure sustained liquidity.
Income Statement
87
Very Positive
XRF Scientific Limited has shown a strong revenue growth rate of 8.45% from 2023 to 2024, with significant gross profit and net profit margins at 43.88% and 14.85% respectively for 2024. The company also maintains a robust EBIT margin of 24.15% and an EBITDA margin of 25.61%, indicating solid operational efficiency. However, monitoring future revenue growth is crucial to maintain this trajectory.
Balance Sheet
80
Positive
The company exhibits financial stability with a low debt-to-equity ratio of 0.06, reflecting conservative leverage. A healthy return on equity (ROE) of 16.19% suggests effective use of shareholders' funds. An equity ratio of 80.43% underscores strong financial independence, minimizing risk of solvency issues. Nonetheless, maintaining such low leverage might limit growth potential.
Cash Flow
75
Positive
XRF Scientific Limited experienced a decrease in operating cash flow to net income ratio from 2023 to 2024, but maintains a positive free cash flow to net income ratio of 0.73, indicating sufficient cash generation. However, the free cash flow growth rate declined by 15.56%, warranting attention to reverse this trend for sustained liquidity and investment capacity.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
60.08M59.84M55.17M40.01M31.29M29.08M
Gross Profit
27.43M26.27M22.00M16.46M12.89M11.34M
EBIT
15.23M14.45M12.76M8.79M6.38M4.84M
EBITDA
15.97M15.32M13.22M9.44M8.05M5.86M
Net Income Common Stockholders
9.42M8.89M7.69M6.08M5.13M3.12M
Balance SheetCash, Cash Equivalents and Short-Term Investments
8.13M12.05M10.40M6.65M5.26M3.63M
Total Assets
66.27M68.23M65.55M55.56M48.37M45.17M
Total Debt
4.57M3.38M4.31M3.51M1.44M1.94M
Net Debt
-3.56M-8.67M-6.09M-3.14M-3.82M-1.70M
Total Liabilities
12.07M12.69M15.97M12.21M9.27M9.53M
Stockholders Equity
54.21M54.89M49.25M43.48M39.10M35.64M
Cash FlowFree Cash Flow
9.37M6.45M7.63M2.63M3.86M3.45M
Operating Cash Flow
10.37M8.09M8.42M3.15M4.51M4.20M
Investing Cash Flow
-2.03M-1.64M-782.43K-1.11M-652.62K-753.41K
Financing Cash Flow
-8.53M-4.80M-3.88M-648.95K-2.24M-3.05M

XRF Scientific Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.56
Price Trends
50DMA
1.62
Negative
100DMA
1.75
Negative
200DMA
1.71
Negative
Market Momentum
MACD
-0.01
Positive
RSI
42.28
Neutral
STOCH
34.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:XRF, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.61, below the 50-day MA of 1.62, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.28 is Neutral, neither overbought nor oversold. The STOCH value of 34.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:XRF.

XRF Scientific Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUXRF
70
Outperform
AU$219.24M23.0418.04%2.44%6.00%10.26%
51
Neutral
$2.04B-1.15-21.24%3.95%2.91%-30.44%
$306.23M-133.28%
$76.87B28.0115.38%1.73%
AURMD
79
Outperform
AU$57.06B28.3825.23%1.31%10.54%38.69%
AUBTH
55
Neutral
$176.66M-33.75%-11.19%-174.51%
AUALC
54
Neutral
AU$123.55M-5.63%-11.96%7.50%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:XRF
XRF Scientific Limited
1.56
0.25
19.08%
BRCHF
BrainChip Holdings
0.16
0.01
6.67%
CMXHF
CSL
163.58
-20.05
-10.92%
AU:BTH
Bigtincan Holdings Ltd
0.22
0.12
120.00%
AU:ALC
Alcidion Group Limited
0.09
0.04
80.00%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
39.02
7.57
24.07%

XRF Scientific Limited Corporate Events

XRF Scientific Director Increases Shareholding
May 26, 2025

XRF Scientific Limited announced a change in the director’s interest, with Vance Stazzonelli acquiring 10,000 ordinary shares, increasing his total to 850,000 shares. This change, executed through a combination of off-market and on-market trades, reflects ongoing adjustments in the company’s leadership investments, potentially impacting stakeholder perceptions and the company’s market dynamics.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Reports Mixed Results in March 2025 Quarter
Apr 15, 2025

XRF Scientific Limited reported a mixed performance in its March 2025 quarterly trading report, with a 9% decrease in revenue to $13.9 million compared to the previous year, but a 5% increase in profit before tax to $3.4 million. The company continues to see growth potential in international markets, driven by the mining industry and international sales, particularly in Asia, the Americas, and Europe. Despite global trade tensions, XRF remains focused on expanding its international sales and exploring new product developments and M&A opportunities.

XRF Scientific Limited Announces Director’s Interest Change
Mar 14, 2025

XRF Scientific Limited has announced a change in the director’s interest notice, specifically regarding David Brown’s indirect interest in the company’s securities. On March 13 and 14, 2025, Brown acquired 32,000 ordinary shares through an on-market trade, increasing his indirect holdings to 3,466,128 shares. This transaction, valued at $56,960, reflects ongoing adjustments in the company’s leadership investment strategies, potentially impacting stakeholder perceptions and the company’s market positioning.

XRF Scientific Limited Announces Quotation of New Securities
Mar 12, 2025

XRF Scientific Limited announced the quotation of 42,886 ordinary fully paid securities on the ASX, issued under an employee incentive scheme. This move may enhance the company’s market presence and provide additional liquidity, potentially benefiting stakeholders by aligning employee interests with company performance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.